000117224 001__ 117224
000117224 005__ 20240319080952.0
000117224 0247_ $$2doi$$a10.3390/pharmaceutics14030636
000117224 0248_ $$2sideral$$a128797
000117224 037__ $$aART-2022-128797
000117224 041__ $$aeng
000117224 100__ $$aChristou, E.
000117224 245__ $$aIron–Gold Nanoflowers: A Promising Tool for Multimodal Imaging and Hyperthermia Therapy
000117224 260__ $$c2022
000117224 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117224 5203_ $$aThe development of nanoplatforms prepared to perform both multimodal imaging and combined therapies in a single entity is a fast-growing field. These systems are able to improve diagnostic accuracy and therapy success. Multicomponent Nanoparticles (MCNPs), composed of iron oxide and gold, offer new opportunities for Magnetic Resonance Imaging (MRI) and Computed To-mography (CT) diagnosis, as well as combined therapies based on Magnetic Hyperthermia (MH) and Photothermal Therapy (PT). In this work, we describe a new seed-assisted method for the synthesis of Au@Fe Nanoparticles (NPs) with a flower-like structure. For biomedical purposes, Au@Fe NPs were functionalized with a PEGylated ligand, leading to high colloidal stability. Moreover, the as-obtained Au@Fe-PEG NPs exhibited excellent features as both MRI and CT Contrast Agents (CAs), with high r2 relaxivity (60.5 mM-1·s-1 ) and X-ray attenuation properties (8.8 HU mM-1·HU). In addition, these nanoflowers presented considerable energy-to-heat conversion under both Alternating Magnetic Fields (AMFs) (¿T ˜ 2.5¿C) and Near-Infrared (NIR) light (¿T ˜ 17¿C). Finally, Au@Fe-PEG NPs exhibited very low cytotoxicity, confirming their potential for theranostics applications. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
000117224 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/PGC2018-096016-B-I00$$9info:eu-repo/grantAgreement/ES/MICINN/PID2020-113108RB-I00/AEI/10.13039/50110001103$$9info:eu-repo/grantAgreement/ES/MICINN/PID2020-118448RB-C21$$9info:eu-repo/grantAgreement/ES/MINECO/CTQ2017-86655-R
000117224 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000117224 590__ $$a5.4$$b2022
000117224 592__ $$a0.795$$b2022
000117224 591__ $$aPHARMACOLOGY & PHARMACY$$b50 / 278 = 0.18$$c2022$$dQ1$$eT1
000117224 593__ $$aPharmaceutical Science$$c2022$$dQ1
000117224 594__ $$a6.9$$b2022
000117224 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000117224 700__ $$aPearson, J. R.
000117224 700__ $$aBeltrán, A. M.
000117224 700__ $$0(orcid)0000-0002-0970-1917$$aFernández-Afonso, Y.
000117224 700__ $$0(orcid)0000-0003-2366-3598$$aGutiérrez, L.$$uUniversidad de Zaragoza
000117224 700__ $$0(orcid)0000-0003-1081-8482$$ade la Fuente, J. M.
000117224 700__ $$aGámez, F.
000117224 700__ $$aGarcía-Martín, M. L.
000117224 700__ $$aCaro, C.
000117224 7102_ $$12009$$2750$$aUniversidad de Zaragoza$$bDpto. Química Analítica$$cÁrea Química Analítica
000117224 773__ $$g14, 3 (2022), 636 - [11 pp]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000117224 8564_ $$s2378824$$uhttps://zaguan.unizar.es/record/117224/files/texto_completo.pdf$$yVersión publicada
000117224 8564_ $$s2832088$$uhttps://zaguan.unizar.es/record/117224/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117224 909CO $$ooai:zaguan.unizar.es:117224$$particulos$$pdriver
000117224 951__ $$a2024-03-18-13:11:51
000117224 980__ $$aARTICLE